Business Context and Reporting Period
This Form 8-K Current Report was filed by MacroGenics, Inc. on August 13, 2025. The filing primarily addresses a significant change in executive leadership and the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive appointments and employment terms.
Material Changes
- Executive Appointment: The Board of Directors appointed Eric Risser as President, Chief Executive Officer, and a Class I Director, effective August 13, 2025. Mr. Risser previously served as the Company's Chief Operating Officer.
- Compensation Structure: An amended employment agreement establishes an annual base salary of $625,000 and eligibility for annual incentive compensation of up to 60% of base salary.
- Equity Grant: Mr. Risser received a stock option award to purchase 550,000 shares of common stock at the closing price on the effective date.
- Severance Provisions:
- Without Cause/Good Reason (No Change of Control): 1.0x base salary + 1.0x target bonus (prorated), 12 months of base salary paid in installments, and 18 months of COBRA premiums.
- Without Cause/Good Reason (With Change of Control): 1.5x base salary + 1.5x target bonus, 12 months of base salary paid in installments, 18 months of COBRA premiums, and acceleration of all unvested equity awards.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or specific risk factors beyond the standard disclosure regarding the executive transition. The press release accompanying this filing is incorporated by reference but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the Amended Employment Agreement when filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2025.
- Review the definitive proxy statement filed on April 11, 2025, for Eric Risser's complete biography.
- Confirm the closing stock price on August 13, 2025, to determine the exercise price of the 550,000 granted options.
- Monitor future filings for any changes to the Board composition or additional executive appointments.